Experienced partner

SSS International Clinical Research has long-standing operational experience in many therapeutic areas:

  • Over 250 projects in more than 20 indication areas
  • A number of landmark EU-wide studies
  • Experience with ‚big pharma‘ (4 out of the top 10)
  • Broad customer spectrum: pharmaceutical companies, biotech firms, universities (Investigator Initiated Trials), diagnostics and medical device suppliers

Wide-ranging expertise

Indications involved in the last 140 studies performed by SSS

Haemato-Oncology

SSS has a wealth of proven expertise in haemato-oncology. In past and present projects, we have worked with hundreds of sites and built up an extensive network. We are currently working with key opinion leaders in the field. Several of the haemato-oncology projects recently completed with our involvement have led to successful market launches. Specifically, we have worked or are currently engaged in the following indications:

  • Acute lymphoblastic leukaemia (ALL)
  • Acute myeloid leukaemia (AML)
  • Chronic myelogenous leukaemia (CML)
  • Hodgkin’s lymphoma (HL)
  • Mantle cell lymphoma (MCL)
  • Follicular lymphoma (FL)
  • Multiple myeloma (MM)
  • Myelofibrosis
  • Refractory B-cell malignancies

Project sponsors in these areas are biotechnology and pharmaceutical companies, but we have also received projects from universities and scientific study groups (investigator initiated trials).

Cardiovascular

SSS has conducted cardiovascular disease research projects in phase II and III trials and non-interventional studies. We work in a wide variety of indications including arterial fibrillation, hypertension and heart failure.

Respiratory

The 15 respiratory tract studies we performed over the last 10 years have allowed us to build up a solid clinical network in pulmonology, with study activities including numerous projects in chronic obstructive pulmonary disease (COPD).

Neurology

Our involvement in neurology trials has mainly focused on dementia and multiple sclerosis. We played a key role in the approval of a blockbuster medication which reached sales of more than USD 3 billion in 2017 alone.

© 2018 SSS International Clinical Research